Raymond James Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $208
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Gary Nachman has initiated coverage on Alnylam Pharmaceuticals with an Outperform rating and a price target of $208.
September 29, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam Pharmaceuticals has been given an Outperform rating and a price target of $208 by Raymond James.
The Outperform rating and high price target given by Raymond James indicates a positive outlook for Alnylam Pharmaceuticals. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100